CFTR and cystic fibrosis: Development of eluforsen, an ASO that aims to insert the three missing bases in the F508del CFTR mRNA through an unknown mechanism, has recently been suspended, despite showing potential to improve lung function in homozygous F508del CF patients (Sermet‐Gaudelus et al, 2019; Drevinek et al, 2020).